Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 58 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerStatus unknownNCT04750083Phase 2/3
• Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.CompletedNCT04749602Phase 2
• A Study of HX008 for the Treatment of Patients With Malignant MelanomaStatus unknownNCT04749485Phase 2
• Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With DurvalumabTerminatedNCT04748419Phase 1/2
• Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After SurgeryStatus unknownNCT04741490Not applicable
• Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung CancerStatus unknownNCT04740021Phase 2
• Metastatic Solid Cancer Clinical TrialActive, not recruitingNCT04739618Phase 2
• Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedNCT04739202Phase 2
• Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerStatus unknownNCT04738630Phase 2
• A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT04736823Phase 2
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Active, not recruitingNCT04736706Phase 3
• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerCompletedNCT04736173Phase 2
• Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell CarcinomaCompletedNCT04735861Phase 2
• A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04734262Phase 2
• A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerCompletedNCT04732598Phase 3
• Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung CancerStatus unknownNCT04731909Not applicable
• Combination Therapy for First Line Treatment of Advanced Cervical CancerStatus unknownNCT04731038Phase 1
• Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung CancerCompletedNCT04730999Phase 2
• Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.Active, not recruitingNCT04730544Phase 2
• Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableStatus unknownNCT04730232Phase 2
• Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaStatus unknownNCT04730219Phase 2
• SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIALTerminatedNCT04729725Phase 1
• Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesTerminatedNCT04729348Phase 2
• Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersActive, not recruitingNCT04729322Phase 2
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04728321Phase 2
• Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO TrialActive, not recruitingNCT04728230Phase 1/2
• Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerActive, not recruitingNCT04727996Phase 2
• Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialActive, not recruitingNCT04727307Phase 2
• Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With ToripalimabStatus unknownNCT04727164Phase 1
• Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid CarcinomaStatus unknownNCT04725448Phase 2
• Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
• Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable MelanomaActive, not recruitingNCT04722575Phase 2
• Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedNCT04721301Phase 1
• Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerActive, not recruitingNCT04721132Phase 2
• A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCCompletedNCT04720716Phase 3
• Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.CompletedNCT04720131Phase 2
• Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCCStatus unknownNCT04718909Phase 2
• Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic CancerStatus unknownNCT04718701Phase 2
• Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaActive, not recruitingNCT04718415Phase 2
• Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerCompletedNCT04717154Phase 2
• Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation TherapyActive, not recruitingNCT04716946Phase 2
• PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT04715633Phase 2
• A Phase 2 Trial for Patients With Metastatic Solid CancerActive, not recruitingNCT04713371Phase 2
• Pembrolizumab for the Treatment of Cervical Intraepithelial NeoplasiaActive, not recruitingNCT04712851Phase 2
• A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Phase 3
• Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesActive, not recruitingNCT04711824Phase 1/2
• Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 2
• A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04709276Phase 2
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable MelanomaActive, not recruitingNCT04708418Phase 2
• Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant TumorsStatus unknownNCT04708210Phase 1
• LAG3 PET Imaging in Advanced Solid TumorsActive, not recruitingNCT04706715Phase 1/2
• Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG TreatmentActive, not recruitingNCT04706598Phase 1/2
• Combining Epigenetic And Immune Therapy to Beat Cancer.CompletedNCT04705818Phase 2
• Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
• Sargramostim (GM-CSF) + PD-1WithdrawnNCT04703426Phase 2
• Cryoablation With Pembrolizumab Or Avelumab In Urothelial CarcinomaCompletedNCT04701918Phase 2
• Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingNCT04701307Phase 2
• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Active, not recruitingNCT04700124Phase 3
• Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)CompletedNCT04700072Phase 1/2
• A Study to Evaluate YH001 in Subjects With Advanced Solid TumorsCompletedNCT04699929Phase 1
• Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04699838Phase 2
• FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid TumorsStatus unknownNCT04699643Phase 1/2
• The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04699123Phase 2
• Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2
• Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT04698213Phase 2
• Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer PatientsStatus unknownNCT04696939Phase 2
• The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid TumorsTerminatedNCT04696848Phase 1/2
• Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer PatientsStatus unknownNCT04695470Phase 2
• The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric CancerCompletedNCT04694183Phase 2
• A Study of PY314 in Subjects With Advanced Solid TumorsTerminatedNCT04691375Phase 1
• PD-1 Antibody for Reactive EBV After BMTStatus unknownNCT04690036Early Phase 1
• Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT04682431Phase 1
• Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICCWithdrawnNCT04682249Phase 2
• Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative ResectionStatus unknownNCT04682210Phase 3
• A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical CancerCompletedNCT04680988Phase 2
• Anti-PD1-antibody and Pulsed HHI for Advanced BCCActive, not recruitingNCT04679480Phase 2
• Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentStatus unknownNCT04679064Phase 3
• A Study of Injection HB0025 in Patients With Advanced Solid TumorsStatus unknownNCT04678908Phase 1
• Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)Status unknownNCT04676997Phase 2
• Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTLStatus unknownNCT04676789Phase 2
• A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)TerminatedNCT04675983Phase 3
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerActive, not recruitingNCT04675710Phase 2
• A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic CancerStatus unknownNCT04674956Phase 3
• To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550TerminatedNCT04674748Phase 1
• Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04673448Phase 1
• A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesCompletedNCT04672928Phase 1
• A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLCCompletedNCT04672369Phase 1
• A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung CancerCompletedNCT04672356Phase 1
• Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial CarcinomaCompletedNCT04672330Phase 2
• Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line ImmunotherapyStatus unknownNCT04670913Phase 2
• Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid TumorsCompletedNCT04669899Phase 1/2
• Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaActive, not recruitingNCT04668300Phase 2
• Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial TumorStatus unknownNCT04667793Phase 2
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based TherapyActive, not recruitingNCT04666740Phase 2
• Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCCStatus unknownNCT04665609Phase 3
• Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent MeningiomaActive, not recruitingNCT04659811Phase 2
• Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2
• Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCCTerminatedNCT04659369Phase 1
• Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04658147Phase 1

← Immune Checkpoint Inhibitors overview